ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,166.76
0.03%
Dow Jones
39,183.00
0.16%
Gold vs US Dollar
2,329.63
0.18%
Brent Oil
86.29
1.39%
Bitcoin
63,036.47
0.70%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. XOMA Corporation (XOMAP)

  7. XOMA Corporation (XOMAP) News

XOMA (XOMAP)

XOMA Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XOMAP
DateTimeSourceHeadlineSymbolCompany
20/06/202412:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAPXOMA Corporation
18/06/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XOMAPXOMA Corporation
18/06/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XOMAPXOMA Corporation
13/06/202421:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:XOMAPXOMA Corporation
12/06/202412:30GlobeNewswire Inc.XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review VoucherNASDAQ:XOMAPXOMA Corporation
30/05/202421:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
17/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
17/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
17/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
17/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
17/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
17/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
16/05/202412:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
14/05/202412:30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQNASDAQ:XOMAPXOMA Corporation
09/05/202412:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
09/05/202412:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XOMAPXOMA Corporation
09/05/202412:30GlobeNewswire Inc.XOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAPXOMA Corporation
30/04/202412:30GlobeNewswire Inc.XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%NASDAQ:XOMAPXOMA Corporation
25/04/202412:30GlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAPXOMA Corporation
03/04/202414:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAPXOMA Corporation
21/03/202411:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAPXOMA Corporation
19/03/202420:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAPXOMA Corporation
11/03/202410:56Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:XOMAPXOMA Corporation
08/03/202421:34Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:XOMAPXOMA Corporation
08/03/202412:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
08/03/202412:30GlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAPXOMA Corporation
04/03/202422:24Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:XOMAPXOMA Corporation
28/02/202412:30GlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAPXOMA Corporation
16/02/202414:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
16/02/202413:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAPXOMA Corporation
 Showing the most relevant articles for your search:NASDAQ:XOMAP

Your Recent History

BIT
P1RS76
BNP Paribas Issuance
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved